SCHEDULE: Oaktree Reduces Indivior Stake to 5.69%
Beneficial Ownership Amendment
Oaktree Capital Management and its affiliates have significantly reduced their beneficial ownership in Indivior PLC, selling over 1.6 million shares in December 2025.
Summary
- Oaktree Capital Management and its affiliated funds (Oaktree Value Opportunities Fund, Oaktree London Liquid Value Opportunities Fund, Oaktree Phoenix Investment Fund, Oaktree Capital Management, Oaktree Fund GP I, Oaktree Capital Holdings, and Oaktree Capital Group Holdings GP) have filed Amendment No. 5 to their Schedule 13D.
- The reporting persons now collectively beneficially own 7,108,664 Ordinary Shares of Indivior PLC, representing 5.69% of the outstanding shares.
- This percentage is calculated based on 124,853,897 Ordinary Shares outstanding as of October 1, 2025, as disclosed by Indivior PLC in its Form 10-Q.
- Since the filing of Amendment No. 4 on November 13, 2025, Oaktree entities have sold a total of 1,631,020 Ordinary Shares of Indivior PLC.
- These sales occurred between December 5, 2025, and December 29, 2025, at prices ranging from $35.0812 to $36.3967 per share.
Sentiment
Score: 3
Explanation: The sentiment is negative due to a significant reduction in beneficial ownership by a major institutional investor, Oaktree Capital Management, which sold over 1.6 million shares. This divestment suggests a decreased conviction in Indivior PLC's future prospects from Oaktree's perspective.
Negatives
- Oaktree Capital Management and its affiliates have significantly reduced their beneficial ownership in Indivior PLC, indicating a decreased conviction or portfolio rebalancing.
- The sale of 1,631,020 shares by a major institutional investor could be perceived negatively by the market, potentially signaling a lack of confidence or a shift in investment strategy.
Future Outlook
The filing does not provide any forward-looking statements or guidance from Indivior PLC or Oaktree Capital Management regarding future performance or strategic direction, beyond the implicit indication of Oaktree's reduced investment.
Industry Context
This filing reflects a portfolio adjustment by a significant institutional investor in Indivior PLC, a pharmaceutical company. While the specific reasons for Oaktree's reduction in stake are not disclosed, such moves by large funds can sometimes signal a re-evaluation of the company's prospects within its sector or a broader shift in investment strategy across the pharmaceutical industry.
Stakeholder Impact
- Shareholders: Existing shareholders may view the reduction in Oaktree's stake as a negative signal, potentially leading to downward pressure on the stock price.
- Company Management: Management might face increased scrutiny regarding the company's performance or strategic direction if a major investor is reducing its position.
Key Dates
| Date | Description |
|---|---|
| 2024-10-02 | Original Schedule 13D filed. |
| 2024-11-07 | Amendment No. 1 to Schedule 13D filed. |
| 2024-12-18 | Amendment No. 2 to Schedule 13D filed. |
| 2025-03-04 | Amendment No. 3 to Schedule 13D filed. |
| 2025-10-01 | Date as of which 124,853,897 Ordinary Shares were outstanding, as disclosed in Indivior's Form 10-Q. |
| 2025-10-30 | Date Indivior PLC filed its quarterly report (Form 10-Q) disclosing shares outstanding. |
| 2025-11-13 | Amendment No. 4 to Schedule 13D filed. |
| 2025-12-05 | First reported sale of 139,769 shares at $35.0812. |
| 2025-12-09 | Sale of 47,399 shares at $36.0574. |
| 2025-12-10 | Sale of 139,914 shares at $35.9507. |
| 2025-12-11 | Sale of 50,000 shares at $35.8071. |
| 2025-12-12 | Sales of 31,293 shares at $35.6432 and 150,000 shares at $36.1107. |
| 2025-12-15 | Sale of 218,778 shares at $35.4141. |
| 2025-12-16 | Sales of 77,705 shares at $35.339 and 21,300 shares at $35.476. |
| 2025-12-22 | Sales of 77,600 shares at $36.2984 and 140,000 shares at $36.2642. |
| 2025-12-23 | Sales of 30,635 shares at $36.3863 and 17,154 shares at $36.3967. |
| 2025-12-24 | Date of event which requires filing of this statement; Sale of 200,000 shares at $36.1051. |
| 2025-12-26 | Sale of 19,473 shares at $36.3172. |
| 2025-12-29 | Last reported sale of 275,000 shares at $36.2577. |
| 2025-12-30 | Date of signature for the Schedule 13D Amendment No. 5. |
Recommendation
sellThe significant reduction in Oaktree Capital Management's stake, involving the sale of over 1.6 million shares, signals a potential loss of confidence from a sophisticated institutional investor. While the specific reasons for their divestment are not disclosed, such a move by a major holder often precedes or accompanies negative developments or a re-evaluation of the company's long-term prospects. This action suggests that the stock may face downward pressure or that its upside potential is perceived as limited by a well-informed market participant, warranting a 'sell' recommendation for investors to consider reducing their exposure.
Keywords
Indivior PLC, Oaktree Capital Management, Schedule 13D, Beneficial Ownership, Share Sales, Institutional Investor, Pharmaceuticals, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.